Introduction
Chronic lymphocytic leukaemia (CLL) is a slow-growing (indolent), and usually incurable, blood cancer that causes certain cells in your body, B-cell lymphocytes or B-cells, to become cancerous.1 Although CLL is the second most common indolent blood cancer in people over 70 years of age, there is limited real-world data on patient characteristics, outcomes and treatment strategies used to manage the condition in Australia.
Our client’s challenge
In this case study, our client wanted to know if and how treatment patterns for CLL had changed over the past ten years, since the introduction of newer novel agents. The analysis focused specifically on current treatment patterns, time to next treatment (TTNT), duration of treatment, overall survival (OS) and outcomes of patients with CLL. This information would help our client understand the Australian treatment landscape and guide their medical engagement and access communications for the Australian market.
Prospection’s depth of experience accessing and analysing oncology data in a real-world setting was leveraged to evaluate and identify patient treatment profiles using Australian Pharmaceutical Benefits Scheme (PBS) data.
……………. Download full case study here:
Speak to Prospection today to learn more about about the Prospection platform and its analytics capabilities.
